Journal Information
Vol. 37. Issue 12.
Pages 1009.e1-1009.e3 (December 2018)
Download PDF
More article options
Vol. 37. Issue 12.
Pages 1009.e1-1009.e3 (December 2018)
Case report
Open Access
Feasibility of use of magnesium reabsorbable scaffolds in complex coronary artery disease: True bifurcation, multiple overlapping scaffolds and chronic total occlusion treatment
Exequibilidade de stents bioabsorbíveis de magnésio na doença coronária complexa: bifurcação verdadeira, stents sobrepostos múltiplos e tratamento da oclusão crónica total
Jeremías Bayón
Corresponding author

Corresponding author.
, Melisa Santá-Álvarez, Raymundo Ocaranza-Sánchez, Carlos González-Juanatey
Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain
Article information
Full Text
Download PDF
Figures (2)

We present first-in-human treatment with bioabsorbable magnesium scaffolds for percutaneous coronary intervention in a patient with nickel allergy. We present images from angiography and optical coherence tomography at three months. We also review the current status of these novel devices.

Bioabsorbable magnesium scaffolds
Nickel allergy
Complex percutaneous coronary intervention

Apresentamos pela primeira vez o tratamento com suportes bioabsorbíveis de magnésio na intervenção coronária percutânea complexa de doentes com alergia ao níquel. Incluímos a angiografia e as imagens da tomografia de coerência óptica efetuadas durante um período de três meses. Analisamos também o estado atual deste equipamento inovador.

Suportes bioabsorbíveis de magnésio
Alergia ao níquel
Intervenção coronária percutânea complexa
Full Text

The Magmaris bioabsorbable sirolimus-releasing magnesium scaffold (Biotronik) is the first device of its kind that is clinically tested and with proven safety data. It features a metallic magnesium backbone with corrugated ring design, six crowns and strut thickness of 150×150 μm. In vitro tests have demonstrated greater radial strength, 20% less recoil and 80% more flexibility than the Absorb bioabsorbable sirolimus-releasing polylactic acid (PLLA) scaffold (Abbott).1

The magnesium backbone is coated with a compound called BIOlute, a resorbable PLLA polymer which delivers controlled release of the sirolimus drug for up to 90 days and which is metabolized in the body to carbon dioxide and water. The absorption process is rapid, with 95% of the magnesium being reabsorbed within twelve months.2

A safety study, BIOSOLVE I, enrolled 46 patients with 47 de novo lesions. Three-year follow-up results were obtained from 44 patients, which showed target lesion failure in three cases (6.6%), and no cardiac death or device thrombosis. Seven patients had additional angiographic follow-up at 28±4 months: in-scaffold late luminal loss had improved from 0.51±0.46 mm (median 0.28 mm) at 12 months to 0.32±0.32 mm (median 0.20 mm).3

The 12-month results of BIOSOLVE-II have recently been published, enrolling 123 patients with de novo lesions with a reference diameter between 2.2 mm and 3.7 mm. Quantitative coronary angiography parameters were stable from 6 to 12 months (paired data of 42 patients: in-segment late lumen loss 0.20±0.21 mm vs. 0.25±0.22 mm, p=0.117; in-scaffold late lumen loss 0.37±0.25 mm vs. 0.39±0.27 mm, p=0.446, respectively. Intravascular ultrasound demonstrated preserved minimal luminal area at six months (6.24±1.15 mm2 after percutaneous coronary intervention [PCI] vs. 6.21±1.22 mm2 at six months), with a small neointimal area (0.08±0.09 mm2). Optical coherence tomography (OCT) detected no intraluminal masses. Target lesion failure was observed in 3.4%, with no definite or probable scaffold thrombosis.4

Current recommendations for the Magmaris implant are de novo coronary lesions with a vessel diameter near the nominal size of the scaffold and a length shorter than the device. Among lesions not recommended or those in which special care has to be taken are total chronic occlusion, excessive tortuosity and side branches (bifurcations) greater than 2 mm in diameter.5

Case report

We present the case of a 65-year-old male with nickel allergy who was admitted to the hospital with non-ST-elevation acute coronary syndrome. Coronary angiography showed significant two-vessel coronary disease not suitable for surgical revascularization because of small caliber and diffuse disease. There were multiple tandem lesions from the proximal to the distal left anterior descending (LAD) artery, bifurcated (Medina 1,1,1) with a diagonal branch, and a chronic total occlusion (CTO) in the mid circumflex (CX) (Figure 1).

Figure 1.

Coronary angiography at baseline, post-percutaneous intervention with implantation of Magmaris devices, and follow-up at three months. CX: circumflex; LAD: left anterior descending.


The patient was on aspirin so a loading dose of 180 mg ticagrelor was added. For the coronary angiography 8000 U heparin (weight-adjusted) and 300 μg intracoronary nitroglycerine were administered, in order to obtain a better assessment of the actual size of the coronary arteries. No imaging techniques were performed because of difficulty in crossing the lesion.

The LAD was treated, first with predilatation with a 3.0 mm×20 mm non-complaint balloon in the distal LAD and the diagonal branch, and a 3.5 mm×20 mm balloon in the proximal LAD (balloon-scaffold ratio 1:1). Sequential and overlapping Magmaris scaffolds were then implanted (leaving 1 mm between the devices) from the distal LAD (one 3 mm×15 mm and two 3.5 mm×25 mm) to the bifurcation with the diagonal. StentBoost image enhancement (Philips) was used to adjust the overlap. Two more Magmaris scaffolds were then implanted in the median LAD (3.5 mm×25 mm) and the diagonal (3 mm×15 mm) by the reverse T and protrusion technique. The CTO of the CX was treated with a 3 mm×25 mm Magmaris. The scaffolds were implanted according to the manufacturer's recommendations to adequately predilate the lesion, select a device diameter very similar to vessel size, and postdilate without exceeding 0.6 mm above the nominal size of the device (Figure 1). In this case, we used non-compliant balloons with a 1:1 ratio except for the scaffold in the proximal LAD, which was postdilated with a 4.0 mm×20 mm non-compliant balloon. The final result was confirmed by OCT.

The patient was discharged with recommendation for 12 months dual antiplatelet therapy with aspirin 100 mg daily and ticagrelor 90 mg twice daily.

At three months, with no symptoms and with the patient's consent, coronary angiography was repeated (Figure 1). Three-month OCT showed appropriate strut apposition and partial covering of the majority of the struts (Figure 2).

Figure 2.

Optical coherence tomography images of the left anterior descending (LAD) and circumflex (CX) arteries, showing adequate apposition with partial covering of the struts. PCI: percutaneous coronary intervention.


We present first-in-human complex PCI in a patient with nickel allergy treated with Magmaris bioabsorbable sirolimus-releasing magnesium scaffolds (Biotronik). We highlight the good apposition in the CTO lesion and the true bifurcation and overlapping in the LAD, with good results on OCT. This novel device is becoming a real option in these patients.

Conflicts of interest

The authors have no conflicts of interest to declare.

W. Schmidt, P. Behrens, C. Brandt-Wunderlich, et al.
In vitro performance investigation of bioresorbable scaffolds – standard tests for vascular stents and beyond.
Cardiovasc Revasc Med, 17 (2016), pp. 375-383
R. Waksman, P. Zumstein, M. Pritsch, et al.
Second-generation magnesium scaffold Magmaris, device design, and preclinical evaluation in a porcine coronary artery model.
EuroIntervention, 13 (2017), pp. 440-449
M. Haude, R. Erbel, P. Erne, et al.
Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
EuroIntervention, 12 (2016), pp. e160-e166
M. Haude, H. Ince, A. Abizaid, et al.
Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
Eur Heart J, 37 (2016), pp. 2701-2709
J. Fajadet, M. Haude, M. Joner, et al.
Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016.
EuroIntervention, 12 (2016), pp. 828-833
Copyright © 2018. Sociedade Portuguesa de Cardiologia
Revista Portuguesa de Cardiologia (English edition)

Subscribe to our newsletter

Article options
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

By checking that you are a health professional, you are stating that you are aware and accept that the Portuguese Journal of Cardiology (RPC) is the Data Controller that processes the personal information of users of its website, with its registered office at Campo Grande, n.º 28, 13.º, 1700-093 Lisbon, telephone 217 970 685 and 217 817 630, fax 217 931 095, and email I declare for all purposes that the information provided herein is accurate and correct.